Intel 18A
The multipolar supply narrative is a taxpayer-funded mirage. Intel and Samsung are bleeding billions in foundry losses while failing to match TSMC's manufacturing scale and silicon yields.
Foxconn / TSMC
File open 12 October 2026: Foxconn / TSMC / Multipolar Supply.
Foxconn / TSMC
Marcus on Foxconn / TSMC: the spin vs the invoice.
Foxconn / TSMC
Forensic audit of Foxconn / TSMC under Multipolar Supply.
Copper Deficit
Marcus exposes the physical reality behind AI grid modernization, arguing that software updates and algorithmic routing cannot fix a global copper deficit or replace rusting physical transformers.
Cassandra Protocol
Live date: 08 October 2026. The Cassandra Archive opens the file on Nexans and Quanta. We examine the €7.9 billion grid modernization mirage, a scenario where corporate ledgers hallucinate infinite copper against a crushing physical supply chain deficit.
copper shortage
Nexans' €7.9 billion backlog isn't market dominance; it's a massive liability. We strip away the M&A camouflage to expose the projected 1.5 million-ton global copper deficit and the supply chain bottlenecks destroying the grid modernization narrative.
Cassandra Protocol
Live as of 06 October 2026. The Cassandra Archive opens the ledger on Eaton, exploring the dangerous intersection of digital sleight of hand and physical grid decay.
Eaton
Marcus dismantles the illusion of coding our way out of a physical copper deficit, exposing the dangerous friction between high-margin software dashboards and rusting infrastructure.
Exact Sciences
Exposing the Adjusted EBITDA double-speak behind Exact Sciences' precision oncology pipeline and the structural trap of the early cancer detection market.
Cassandra Protocol
02 October 2026. The Q4 archives open on Natera and the brittle architecture of precision oncology. We dissect the miracle of early cancer detection against the crumbling infrastructure of healthcare reimbursement. Step into the cold and press play.
Natera
Natera is selling a subscription model for survival, but the financial architecture is bleeding. An analysis of the reimbursement void in precision oncology and the corporate mirage of standard-of-care diagnostics.